Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4KVN

Crystal structure of Fab 39.29 in complex with Influenza Hemagglutinin A/Perth/16/2009 (H3N2)

Summary for 4KVN
Entry DOI10.2210/pdb4kvn/pdb
DescriptorHemagglutinin, Human IgG Heavy Chain, Human IgG Light Chain, ... (9 entities in total)
Functional Keywordsigg, antibody, immune system
Biological sourceInfluenza A virus
More
Total number of polymer chains3
Total formula weight107185.39
Authors
Fong, R.,Swem, L.R.,Lupardus, P.J. (deposition date: 2013-05-22, release date: 2013-08-07, Last modification date: 2024-11-20)
Primary citationNakamura, G.,Chai, N.,Park, S.,Chiang, N.,Lin, Z.,Chiu, H.,Fong, R.,Yan, D.,Kim, J.,Zhang, J.,Lee, W.P.,Estevez, A.,Coons, M.,Xu, M.,Lupardus, P.,Balazs, M.,Swem, L.R.
A Novel In vivo Human Plasmablast Enrichment Technique Allows Rapid Identification of Therapeutic Anti-Influenza A Antibodies
Cell Host Microbe, 14:93-103, 2013
Cited by
PubMed Abstract: Recent advances enabling the cloning of human immunoglobulin G genes have proven effective for discovering monoclonal antibodies with therapeutic potential. However, these antibody-discovery methods are often arduous and identify only a few candidates from numerous antibody-secreting plasma cells or plasmablasts. We describe an in vivo enrichment technique that identifies broadly neutralizing human antibodies with high frequency. For this technique, human peripheral blood mononuclear cells from vaccinated donors are activated and enriched in an antigen-specific manner for the production of numerous antigen-specific plasmablasts. Using this technology, we identified four broadly neutralizing influenza A antibodies by screening only 840 human antibodies. Two of these antibodies neutralize every influenza A human isolate tested and perform better than the current anti-influenza A therapeutic, oseltamivir, in treating severe influenza infection in mice and ferrets. Furthermore, these antibodies elicit robust in vivo synergism when combined with oseltamivir, thus highlighting treatment strategies that could benefit influenza-infected patients.
PubMed: 23870317
DOI: 10.1016/j.chom.2013.06.004
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.1 Å)
Structure validation

246905

PDB entries from 2025-12-31

PDB statisticsPDBj update infoContact PDBjnumon